CX3CL1 Protein (AA 22-105)

Catalog No. ABIN2666624

This Recombinant CX3CL1 protein is expressed in Escherichia coli (E. coli).

Quick Overview for CX3CL1 Protein (AA 22-105) (ABIN2666624)

Target: CX3CL1 (Chemokine (C-X3-C Motif) Ligand 1 (CX3CL1))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS), Cytometry by Time of Flight (CyTOF)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 22-105

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its property to chemoattract BaF3-mCX3CR1 transfectants in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored from -20 °C to -70 °C. Stock solutions can also be prepared at 50-100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2-1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in 10 mM NaH2PO4, 0.15 M NaCl, pH 7.2.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CX3CL1 (Chemokine (C-X3-C Motif) Ligand 1 (CX3CL1))

Alternative Name: CX3CL1

Background: CX3CL1 is a unique chemokine subclass, synthesized as a transmembrane molecule It consists of an extracellular NH2-terminal domain, a mucin-like stalk, a transmembrane α helix, and a short cytoplasmic tail. CX3CL1 exists in two forms: as a membrane-anchored or as a shed 80-95K glycoprotein. Soluble CX3CL1 is generated by limited proteolysis on the cell surface, and a disintegrin and metallopeptidase 10 (ADAM10) and ADAM17/tumor necrosis factor-α-converting enzyme (ADAM17/TACE) participate in this shedding. It has been suggested that ADAM10 acts in the constitutive shedding, and ADAM17 acts in response to cell activation. CX3CL1 is associated with the development of different diseases such as rheumatoid arthritis (RA), rheumatoid vasculitis (RV), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), scleroderma, multiple sclerosis, and atherosclerosis. Soluble fractalkine has been detected in the cerebrospinal fluid of patients with neuropsychiatric lupus, and is present at higher levels in the serum of patients with SS, RA, and type 2 diabetes than in control subjects.

Molecular Weight: The 85 amino acid recombinant protein has a predicted molecular mass of approximately 9.59 kDa. The DTT-reduced protein migrates at approximately 13 kDa and non-reduced protein migrates at 15.5 kDa by SDS-PAGE. The N-terminal amino acid is Meteonine.

Pathways: Synaptic Membrane